瘤生物学和癌症治疗中的MDM2:对当前临床试验的审查
Francesco Russano1, Mattia Sturlese2, Luigi Dall'Olmo1,3
1Soft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology (IOV), 35128 Padua, Italy.
International journal of molecular sciences
|January 10, 2026
概括
准鼠类双分钟2 (MDM2) 基因,该基因通过抑制瘤抑制剂p53促进癌症,显示出有前途. MDM2 抑制剂旨在恢复p53活性,改善癌症治疗结果.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物开发 药物开发
背景情况:
- 鼠类双分钟2 (MDM2) 基因产物是一种E3泛酸酶,可以负面调节瘤抑制剂p53.
- 过度表达MDM2与各种癌症有关,导致p53活性降低,瘤启动和治疗阻力.
- 此外,MDM2还具有对细胞周期进展和DNA修复至关重要的p53独立功能.
研究的目的:
- 审查研究MDM2抑制作为癌症治疗的临床试验.
- 突出针对MDM2-p53相互作用的治疗潜力.
- 讨论MDM2在野生型TP53.3癌症中的作用.
主要方法:
- 对MDM2抑制剂的临床试验数据的审查.
- 分析MDM2的作用机制,包括p53依赖和独立的途径.
- 在各种恶性瘤中检查MDM2表达模式.
主要成果:
- 增加的MDM2表达与脂肪肉瘤,乳腺癌和质母细胞瘤等癌症的预后不佳相关.
- MDM2 抑制剂正在临床开发中,以破坏 MDM2-p53 相互作用.
- 通过MDM2抑制恢复p53的瘤抑制功能是关键的治疗策略.
结论:
- 在瘤学中,MDM2是经过验证的治疗点.
- MDM2 抑制剂在具有野生型TP53.3的瘤中对重新激活p53具有前景.
- 针对MDM2提供了一种潜在的策略,以改善癌症治疗结果.
相关概念视频
Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
Therapeutic Drug Monitoring: Affecting Factors
196
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
196
Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Drugs that Stabilize Microtubules
2.6K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K


